Peachtree Corners, GEORGIA1 Active Studies

Pulmonary Embolism Clinical Trials in Peachtree Corners, GEORGIA

Find 1 actively recruiting pulmonary embolism clinical trials in Peachtree Corners, GEORGIA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
405
Enrolling

Recruiting Pulmonary Embolism Studies in Peachtree Corners

About Pulmonary Embolism Clinical Trials in Peachtree Corners

Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.

There are currently 1 pulmonary embolism clinical trials recruiting participants in Peachtree Corners, GEORGIA. These studies are seeking a combined 405 participants. Research is being sponsored by AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Embolism Clinical Trials in Peachtree Corners — FAQ

Are there pulmonary embolism clinical trials in Peachtree Corners?

Yes, there are 1 pulmonary embolism clinical trials currently recruiting in Peachtree Corners, GEORGIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Peachtree Corners?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Peachtree Corners research site will contact you about next steps.

Are clinical trials in Peachtree Corners free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Peachtree Corners studies also compensate for your time and travel.

What pulmonary embolism treatments are being tested?

The 1 active trials in Peachtree Corners are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.

Data updated March 2, 2026 from ClinicalTrials.gov